drugset
Drugs / LIBP-Rec-Vaccine
last change Dec 2023 re-read 3 minutes ago

LIBP-Rec-Vaccine

Developed for
COVID-19
Investigated by
Beijing Institute of Biological Products Co Ltd. · China National Biotec Group Company Limited · Lanzhou Institute of Biological Products Co., Ltd · National Vaccine and Serum Institute, China

Trials 1

today NCT05599516 · Ph 3
2023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 3 NCT05599516 Nov 2022 → Oct 2023 COVID-19 National Vaccine and Serum Institute, China Unknown No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as LIBP-Rec-Vaccine ClinicalTrials.gov intervention name — accepted as the source's own label NCT05599516 ↗
Route Intramuscular “Intramuscular injection of LIBP-Rec-Vaccine in the deltoid muscle of the upper arm” NCT05599516 ↗